Aarti Pharmalabs Stock Prediction 2026: Expert Analysis, Forecast Scenarios and Full Stock Review

The Aarti Pharmalabs stock prediction for 2026 from leading brokerages covers a range reflecting sector dynamics, earnings trajectory and the macro environment. All estimates may or may not be achieved. Treat any Aarti Pharmalabs share price prediction as one data point and not as a guarantee of future performance.

This article reviews every dimension of the Aarti Pharmalabs stock forecast analysts are tracking, including key drivers, bull and bear scenarios and the primary risks. Verify all figures with the latest brokerage reports before any investment decision.

Click Here – Get Free Investment Predictions

What Analysts Predict for Aarti Pharmalabs Stock in 2026

Analyst consensus on the Aarti Pharmalabs stock prediction for 2026 is tracked by leading brokerages. The table below shows the latest available data from JM Financial and Kotak Securities. All figures are sourced from publicly available research and should be verified before publishing.

Brokerage	Rating	Aarti Pharmalabs Stock Prediction (Rs)	Updated
JM Financial	Neutral	Rs 760	2026
Kotak Securities	Neutral	Rs 710	2026
Analyst Consensus	—	Rs 735	2026

The Aarti Pharmalabs stock prediction range reflects genuine difference of opinion on demand recovery, margin trajectory and sector headwinds. The implied upside in the Aarti Pharmalabs stock forecast from the current price of Rs 649.4 may or may not be realised by end of 2026.

Aarti Pharmalabs Company Overview

Aarti Pharmalabs is a significant player in India’s pharmaceutical industry with a presence across domestic formulations, US generics and specialty segments. The Aarti Pharmalabs stock prediction for 2026 reflects both the pipeline growth potential and regulatory risk.

Metric	Value
NSE Ticker	AARTIPHARM
Sector	Pharmaceuticals and Healthcare
CMP	Rs 649.4 (2026)
52 Week High	Rs 972
52 Week Low	Rs 584
Market Cap	Rs 5,872 Cr
P/E Ratio	32.9
Aarti Pharmalabs Stock Prediction Consensus (12M)	Rs 735

Aarti Pharmalabs Stock Prediction by Time Horizon

Analysts split the Aarti Pharmalabs share price prediction across time frames as near-term drivers differ materially from the long-term view.

Short-Term Aarti Pharmalabs Stock Prediction

The near-term Aarti Pharmalabs stock forecast reflects current sentiment, sector news and upcoming earnings prints. Key support and resistance levels around Rs 649.4 are being watched closely. A short-term Aarti Pharmalabs share price prediction carries the most uncertainty of any time horizon.

12-Month Aarti Pharmalabs Stock Prediction

JM Financial targets Rs 760 (Neutral) and Kotak Securities targets Rs 710 (Neutral). Most desks refresh their Aarti Pharmalabs stock forecast within two to four weeks of each quarterly earnings print. The Aarti Pharmalabs share price prediction should be verified against the most recent analyst reports.

Long-Term Aarti Pharmalabs Stock Prediction

The long-term Aarti Pharmalabs stock prediction is built on assumptions about demand recovery, margin expansion and revenue diversification in the Pharmaceuticals and Healthcare sector. The long-term Aarti Pharmalabs share price prediction carries the most uncertainty and should be treated as directional guidance only.

Aarti Pharmalabs Stock Forecast: Key Factors

The following four factors appear consistently in research reports on the Aarti Pharmalabs stock prediction and are the primary inputs into the bull and bear case scenarios.

US Generic Revenue

US generics revenue is the most watched metric in the Aarti Pharmalabs stock forecast. USFDA approval timelines and price erosion rates directly affect the Aarti Pharmalabs share price prediction from most research desks.

Domestic Formulations Growth

Domestic formulation growth provides a stable base that supports the Aarti Pharmalabs stock prediction even when export growth faces headwinds.

R&D Pipeline

The depth and commercialization pace of the R&D pipeline is a key variable in the long-term Aarti Pharmalabs share price prediction. New product approvals are cited as catalysts for the Aarti Pharmalabs stock prediction.

EBITDA Margin

Sustained EBITDA margin expansion is typically the basis for the bullish Aarti Pharmalabs stock forecast. Margin recovery strengthens the Aarti Pharmalabs share price prediction from most research desks.

Aarti Pharmalabs Stock Prediction: Bull and Bear Scenarios

Scenario	Aarti Pharmalabs Stock Prediction	Key Conditions
Bull Case	Rs 760	Strong execution, margin improvement, favourable macro and sector re-rating
Base Case	Rs 735	Steady performance, gradual recovery, margins hold, growth on track
Bear Case	Rs 584	Demand deterioration, margin pressure, sector de-rating and macro headwinds

The bull case Aarti Pharmalabs stock forecast of Rs 760 assumes most positive variables converge. The base case of Rs 735 is the analyst consensus and may or may not be achieved.

How Analysts Are Reading the Aarti Pharmalabs Stock Story

Analyst reviews of the Aarti Pharmalabs share price prediction highlight the company’s core strengths in Pharmaceuticals and Healthcare alongside near-term headwinds from macro uncertainty, competitive pressure and sector-level challenges. Overall the Aarti Pharmalabs stock prediction consensus is built on real business strengths set against real risks.

Key Risks to the Aarti Pharmalabs Stock Prediction

USFDA Regulatory Risk

Import alerts and warning letters from the USFDA are the most significant risks to the Aarti Pharmalabs stock prediction. A facility closure would force an immediate sharp revision to the Aarti Pharmalabs share price prediction.

Price Erosion in the US

Pricing pressure in US generics compresses the revenue per product and affects the Aarti Pharmalabs stock forecast. Aggressive price erosion pushes the Aarti Pharmalabs share price prediction toward the bear case.

R&D Execution Risk

Delays in clinical trials or approval failures affect the Aarti Pharmalabs stock prediction. The Aarti Pharmalabs share price prediction is particularly sensitive to key pipeline asset announcements.

Currency Risk

A strengthening rupee against the dollar reduces export realisation and affects the Aarti Pharmalabs stock forecast. Currency risk is embedded in conservative Aarti Pharmalabs share price prediction models.

How to Monitor the Aarti Pharmalabs Stock Forecast

Track the Aarti Pharmalabs share price prediction consensus quarterly. After every earnings release, most brokerages revise their Aarti Pharmalabs stock forecast within two weeks. Comparing the revised Aarti Pharmalabs stock prediction to the previous estimate tells you whether analyst sentiment is improving or deteriorating.

Compare the current price of Rs 649.4 with the analyst target range of Rs 760 to Rs 710. A wide Aarti Pharmalabs stock prediction band reflects genuine uncertainty, so position size should reflect that range rather than the midpoint alone.

Review the Aarti Pharmalabs share price prediction every quarter against key business metrics for the Pharmaceuticals and Healthcare sector. A single estimate from any analyst is a point-in-time view and should be treated as one input among many when making any investment decision.

Check Live Aarti Pharmalabs Fundamentals on the Univest Screener

Conclusion

The Aarti Pharmalabs stock prediction for 2026 reflects the analyst community’s assessment of Aarti Pharmalabs’s competitive position, earnings trajectory and macro environment. JM Financial holds a Neutral stance with a target of Rs 760 while Kotak Securities has a Neutral rating with a target of Rs 710, giving an analyst consensus of Rs 735.

The Aarti Pharmalabs stock forecast is set against near-term risks that make the Aarti Pharmalabs share price prediction range wide. Investors should verify any estimate with the latest brokerage reports before using it as an investment reference. The analyst forecast will be revised after every quarterly result, so tracking changes in the Aarti Pharmalabs stock prediction over time is more valuable than relying on any single estimate.

Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice.

Download the Univest iOS App or Univest Android App to track the live Aarti Pharmalabs stock prediction and share price prediction changes in real time.

Frequently Asked Questions on Aarti Pharmalabs Stock Prediction 2026

What is the Aarti Pharmalabs stock prediction for 2026?

Ans. The Aarti Pharmalabs stock prediction for 2026 is based on analyst consensus from JM Financial and Kotak Securities. The consensus target is Rs 735. All estimates may or may not be achieved.

Is the Aarti Pharmalabs stock prediction bullish or bearish?

Ans. JM Financial has a Neutral rating with target Rs 760. Kotak Securities has a Neutral rating with target Rs 710. The Aarti Pharmalabs stock forecast reflects genuine analyst diversity of opinion.

What is the Aarti Pharmalabs share price prediction based on fundamentals?

Ans. The Aarti Pharmalabs share price prediction rests on the US generic pipeline, domestic growth, EBITDA margin and regulatory compliance track record. Analysts tracking Aarti Pharmalabs closely cite these as the primary drivers of the 2026 outlook.

What is the long-term Aarti Pharmalabs stock prediction?

Ans. The long-term Aarti Pharmalabs stock prediction assumes the company sustains its core business drivers over a multi-year horizon. The 12-month consensus of Rs 735 is the nearest reliable anchor point.

What are the key risks to the Aarti Pharmalabs stock prediction?

Ans. The primary risks include sector-specific headwinds, macro uncertainty, regulatory changes and competitive pressure. Every Aarti Pharmalabs stock prediction should be read alongside its risk assumptions.

What does the Aarti Pharmalabs stock forecast say for 2026?

Ans. JM Financial: Neutral target Rs 760. Kotak Securities: Neutral target Rs 710. These Aarti Pharmalabs share price prediction estimates may or may not prove accurate.

Where can I track the latest Aarti Pharmalabs stock prediction?

Ans. Track the latest Aarti Pharmalabs stock prediction on the NSE and BSE websites and on the Univest app and screener for live price and updated analyst targets.